Akela reports net gain of $1.december 31 5 million for three months ended, 2010 Akela Pharma, Inc. , a head in the development of therapeutics for the treatment of pain, and the business’s wholly possessed subsidiary, PharmaForm, today announced its monetary results for the three months and year ended December 31, 2010. December 31 Total consolidated revenues for the three months ended, 2010 were $3.7 million, including $3.0 million of contract services, in comparison with $3.0 million, including $2.4 million of contract services, for the same period during the earlier year.3 million, including $10.2 million of contract companies, as compared to $13.9 million, including $10.6 million of contract services, for 2009. Consolidated net income for the three and a year ended December 31, 2010 were $1.5 million, $0.05 per share, and $1.2 million, $0.04 per talk about, versus losses of $14.1 million, per share, and losses of $21.0 million, per talk about, for the same respective intervals in 2009 2009.The median time from randomization to detection of atrial fibrillation was 84 times in the ICM group and 53 times in the control group. Atrial fibrillation was asymptomatic in 23 of 29 initial episodes in the ICM group and in 2 of 4 first episodes in the control group . With monitoring continued from 6 through 12 months, yet another 10 1st episodes of atrial fibrillation were detected in the ICM group versus 1 in the control group, despite 34 standard ECG studies in 33 sufferers and 12 occurrences of Holter monitoring in 10 patients. Ischemic stroke or TIA occurred in 11 patients in the ICM group, as compared with 18 patients in the control group, through the first six months after randomization and in 15 individuals versus 19 patients during the first 12 weeks.